TrialClinical pharmacokinetics2021

Evaluation of the Pharmacokinetics and Exposure-Response Relationship of Dapagliflozin in Patients without Diabetes and with Chronic Kidney Disease.

Annemarie B van der Aart-van der Beek et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.